Discussion on the nomenclature of recombinant Mycobacterium tuberculosis allergen skin test

doi:10.19982/j.issn.1000-6621.20220486

Abstract

Abstract:

In view of the new tuberculosis infection test recommended by WHO in 2022, the MTB antigen-based skin tests (TBST) for the diagnosis of tuberculosis infection, the authors sorted out the name of new varieties of the same kind that have been listed and are under research, discussed the nomenclature of such products with reference to the principles related to nomenclature of biological products in China, expected to provide discussion and reference for experts from research and development, use and regulatory departments.

Key words: Mycobacterium tuberculosis, Mycobacterium infection, Allergy and immunology, Nomenclature

CLC Number:

Zhao Aihua, Du Weixin, Wang Guozhi, Xu Miao. Discussion on the nomenclature of recombinant Mycobacterium tuberculosis allergen skin test[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 333-335. doi: 10.19982/j.issn.1000-6621.20220486

Figures/Tables 1

References 15

[1]	World Health Organization. Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection. Geneva: World Health Organization, 2022.
[2]	Li F, Xu M, Qin C, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect, 2016, 22(10):889.e9-889.e16. doi:10.1016/j.cmi.2016.07.015. doi: 10.1016/j.cmi.2016.07.015 URL
[3]	Xu M, Lu W, Li T, et al. Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials Clin. Infect Dis, 2022, 74(4):668-677. doi:10.1016/j.cmi.2016.07.015. doi: 10.1016/j.cmi.2016.07.015
[4]	Du WX, Chen BW, Lu JB, et al. Preclinical study and phase I clinical safety evaluation of recombinant Mycobacterium tuberculosis ESAT6 protein. Med Sci Monit Basic Res, 2013, 19:146-152. doi:10.12659/MSMBR.883912. doi: 10.12659/MSMBR.883912
[5]	Starshinova A, Zhuravlev V, Dovgaluk I, et al. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. Int J Mycobacteriol, 2018, 7(1):32-39. doi:10.4103/ijmy.ijmy_17_18. doi: 10.4103/ijmy.ijmy_17_18 pmid: 29516883
[6]	Starshinova A, Dovgalyk I, Malkova A, et al. Recombinant tuberculosis allergen (Diaskintest^®) in tuberculosis diagnostic in Russia (meta-analysis). Int J Mycobacteriol, 2020, 9(4):335-346. doi:10.4103/ijmy.ijmy_131_20. doi: 10.4103/ijmy.ijmy_131_20 pmid: 33323648
[7]	Aggerbeck H, Ruhwald M, Hoff ST, et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS One, 2018, 13(9):e0204554. doi:10.1371/journal.pone.0204554. doi: 10.1371/journal.pone.0204554
[8]	Aggerbeck H, Ruhwald M, Hoff S, et al. Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial. Int J Tuberc Lung Dis, 2019, 23(1):38-44. doi:10.5588/ijtld.18.0137. doi: 10.5588/ijtld.18.0137 pmid: 30572979
[9]	Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J, 2016, 47(3):919-928. doi:10.1183/13993003.01464-2015. doi: 10.1183/13993003.01464-2015 pmid: 26677940
[10]	Sharma SK, Vashishtha R, Chauhan LS, et al. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS One, 2017, 12(1):e0169539. doi:10.1371/journal.pone.0169539. doi: 10.1371/journal.pone.0169539
[11]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva: World Health Organization, 2022.
[12]	World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva: World Health Organization, 2022.
[13]	徐苗, 罗永艾, 黎友伦, 等. 重组结核分枝杆菌11000蛋白对结核分枝杆菌感染的鉴别作用. 中华结核和呼吸杂志, 2006, 29(11): 762-765.
[14]	陈保文, 徐苗, 徐敬华, 等. 结核分枝杆菌RD1区重组11kD蛋白的克隆表达及效力. 中国生物制品学杂志, 2006, 19(5):468-470. doi:10.3969/j.issn.1004-5503.2006.05.009. doi: 10.3969/j.issn.1004-5503.2006.05.009
[15]	中华人民共和国国家药典委员会. 中华人民共和国药典. 北京: 中国医药科技出版社, 2020.

制剂名称	结核分枝杆菌蛋白	结构
重组结核杆菌变态反应原11kDa	ESAT6	11kDa蛋白
注射用结核病变态反应原RP22	ESAT6 和 CFP10	C-E
重组结核杆菌蛋白(D-EC)	ESAT6 和 CFP10	E-E-C-C
重组结核杆菌蛋白(EEC)	ESAT6 和 CFP10	E-E-C
重组结核杆菌蛋白(EM)	ESAT6 和 MBP64	E-M